Hostname: page-component-699b5d5946-24ph4 Total loading time: 0 Render date: 2026-03-09T04:14:39.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab

Published online by Cambridge University Press:  14 July 2025

Toshimitsu Ohashi Open the ORCID record for Toshimitsu Ohashi [Opens in a new window] ,
Nansei Yamada ,
Kosuke Terazawa ,
Hirofumi Shibata ,
Masato Takiwaki ,
Takanori Wakaoka ,
Shigeaki Tanahasi ,
Hiroki Takahashi ,
Bunya Kuze  and
Masami Ohnishi
...Show all authors
Toshimitsu Ohashi*
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan Department of Head and Neck Surgery-Otorhinolaryngology, Ogaki Municipal Hospital, Ogaki, Japan
Nansei Yamada
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu Prefectural General Medical Center, Gifu, Japan
Kosuke Terazawa
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
Hirofumi Shibata
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
Masato Takiwaki
Affiliation:
Department of Otolaryngology, Chuno Kosei Hospital, Seki, Japan
Takanori Wakaoka
Affiliation:
Department of Head and Neck Surgery-Otorhinolaryngology, Ogaki Municipal Hospital, Ogaki, Japan Department of Otolaryngology, Chuno Kosei Hospital, Seki, Japan
Shigeaki Tanahasi
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu Municipal Hospital, Gifu, Japan
Hiroki Takahashi
Affiliation:
Department of Otolaryngology, Japanese Red Cross Takayama Hospital, Takayama, Japan
Bunya Kuze
Affiliation:
Department of Otolaryngology, Central Japan International Medical Center, Minokamo, Japan
Masami Ohnishi
Affiliation:
Department of Head and Neck Surgery-Otorhinolaryngology, Ogaki Municipal Hospital, Ogaki, Japan
Hiromichi Shirato
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu Municipal Hospital, Gifu, Japan Department of Otolaryngology-Head and Neck Surgery, JA Gifu Kouseiren Seino Kosei Hospital, Ibi, Japan
Keisuke Mizuta
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Ichinomiyanishi Hospital, Ichinomiya, Japan
Takenori Ogawa
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
*
Corresponding author: Toshimitsu Ohashi; Email: tohashi@omh.ogaki.gifu.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.

Methods

Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.

Results

Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.

Conclusion

The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.

Keywords

drug response biomarkershead and neck squamous cell carcinomaimmune checkpoint inhibitornivolumabsurvival analyses

Information

Type
Main Article
Information
The Journal of Laryngology & Otology , Volume 139 , Issue 10 , October 2025 , pp. 934 - 940
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Toshimitsu Ohashi takes responsibility for the integrity of the content of the paper

References

Ferris, RL, Blumenschein, G Jr, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67CrossRefGoogle ScholarPubMed
Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54CrossRefGoogle ScholarPubMed
Topalian, SL, Sznol, M, McDermott, DF, Kluger, HM, Carvajal, RD, Sharfman, WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–30CrossRefGoogle ScholarPubMed
Sharma, P, Retz, M, Siefker-Radtke, A, Baron, A, Necchi, A, Bedke, J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–22CrossRefGoogle ScholarPubMed
Kang, YK, Boku, N, Satoh, T, Ryu, MH, Chao, Y, Kato, K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461–71CrossRefGoogle ScholarPubMed
Armand, P, Engert, A, Younes, A, Fanale, M, Santoro, A, Zinzani, PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:1428–39CrossRefGoogle ScholarPubMed
Kato, K, Cho, BC, Takahashi, M, Okada, M, Lin, C-Y, Chin, K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506–17CrossRefGoogle ScholarPubMed
Taube, JM, Klein, A, Brahmer, JR, Xu, H, Pan, X, Kim, JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064–74CrossRefGoogle ScholarPubMed
Daud, AI, Wolchok, JD, Robert, C, Hwu, W-J, Weber, JS, Ribas, A, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34:4102–9CrossRefGoogle Scholar
Goodman, AM, Kato, S, Bazhenova, L, Patel, SP, Frampton, GM, Miller, V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017;16:2598–608CrossRefGoogle Scholar
Johnson, DB, Estrada, MV, Salgado, R, Sanchez, V, Doxie, DB, Opalenik, SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 2016;7:10582CrossRefGoogle ScholarPubMed
Wang, X, Schoenhals, JE, Li, A, Valdecanas, DR, Ye, H, Zang, F, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 2017;77:839–50CrossRefGoogle ScholarPubMed
Li, H, van der Merwe, PA, Sivakumar, S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer 2022;126:1663–75CrossRefGoogle ScholarPubMed
Zheng, H, Liu, X, Zhang, J, Rice, SJ, Wagman, M, Kong, Y, et al. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233–40CrossRefGoogle ScholarPubMed
Arrieta, O, Montes-Servin, E, Hernandez-Martinez, J-M, Cardona, AF, Casas-Ruiz, E, Crispín, JC, et al. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 2017;8:101994–2005CrossRefGoogle ScholarPubMed
Kim, HR, Park, S-M, Seo, S-U, Jung, I, Yoon, HI, Gabrilovich, DI, et al. The ratio of peripheral regulatory T cells to Lox-1(+) polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer. Am J Respir Crit Care Med 2019;199:243–6CrossRefGoogle ScholarPubMed
Chen, P-L, Roh, W, Reuben, A, Cooper, ZA, Spencer, CN, Prieto, PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 2016;6:827–37CrossRefGoogle ScholarPubMed
Boutsikou, E, Domvri, K, Hardavella, G, Tsiouda, D, Zarogoulidis, K, Kontakiotis, T. Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. Ther Adv Med Oncol 2018;10:1758835918768238CrossRefGoogle ScholarPubMed
Vanpouille-Box, C, Formenti, SC. Dual transforming growth factor-β and programmed death-1 blockade: a strategy for immune-excluded tumors? Trends Immunol 2018;39:435–7CrossRefGoogle ScholarPubMed
Wang, M, Zhai, X, Li, J, Guan, J, Xu, S, Li, Y, et al. The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol 2021;12:670391.CrossRefGoogle ScholarPubMed
Lu, C, Zhang, Y-C, Chen, Z-H, Zhou, Q, Wu, Y-L. Applications of circulating tumor DNA in immune checkpoint inhibition: emerging roles and future perspectives. Front Oncol 2022;12:836891CrossRefGoogle ScholarPubMed
Frigola, X, Inman, BA, Krco, CJ, Liu, X, Harrington, SM, Bulur, PA, et al. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett 2012;142:78–82CrossRefGoogle ScholarPubMed
Nakamura, Y, Kitano, S, Takahashi, A, Tsutsumida, A, Namikawa, K, Tanese, K, et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016;7:77404–15CrossRefGoogle ScholarPubMed
Capone, M, Giannarelli, D, Mallardo, D, Madonna, G, Festino, L, Grimaldi, AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 2018;6:74CrossRefGoogle ScholarPubMed
Yasumatsu, R, Wakasaki, T, Hashimoto, K, Nakashima, K, Manako, T, Taura, M, et al. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. Head Neck 2019;41:2610–18CrossRefGoogle ScholarPubMed
Zhang, Y, Chen, S, Chen, H, Li, W. A comprehensive analysis of Glasgow prognostic score (GPS)/the modified Glasgow prognostic score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer. Cancer Med 2023;12:38–48CrossRefGoogle ScholarPubMed
Proctor, MJ, Morrison, DS, Talwar, D, Balmer, SM, O'Reilly, DSJ, Foulis, AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726–34CrossRefGoogle Scholar
McMillan, DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534–40CrossRefGoogle Scholar
Terazawa, K, Ohashi, T, Shibata, H, Ishihara, T, Ogawa, T. Immune-modified Glasgow prognostic score: a new prognostic marker for head and neck cancer. Head Neck 2022;44:2555–63CrossRefGoogle Scholar
Ohashi, T, Akazawa, T, Aoki, M, Kuze, B, Mizuta, K, Ito, Y, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer 2013;133:1107–18CrossRefGoogle ScholarPubMed
Zhao, H, Wu, L, Yan, G, Chen, Y, Zhou, M, Wu, Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263CrossRefGoogle ScholarPubMed
Riedl, JM, Barth, DA, Brueckl, WM, Zeitler, G, Foris, V, Mollnar, S, et al. C-Reactive Protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study. Cancers (Basel) 2020;12:2319CrossRefGoogle ScholarPubMed
Nakamura, Y, Kitano, S, Takahashi, A, Tsutsumida, A, Namikawa, K, Tanese, K, et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016;7:77404–15CrossRefGoogle ScholarPubMed
Park, JC, Durbeck, J, Clark, JR. Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. Mol Clin Oncol 2020;13:87CrossRefGoogle ScholarPubMed
Guo, Y, Wei, L, Patel, SH, Lopez, G, Grogan, M, Li, M, et al. Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy. Clin Lung Cancer 2022;23:345–55CrossRefGoogle Scholar
Dharmapuri, S, Özbek, U, Lin, J-Y, Sung, M, Schwartz, M, Branch, AD, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med 2020;9:4962–70CrossRefGoogle ScholarPubMed
Ota, Y, Takahari, D, Suzuki, T, Osumi, H, Nakayama, I, Oki, A, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol 2020;85:265–72CrossRefGoogle ScholarPubMed
Simonaggio, A, Elaidi, R, Fournier, L, Fabre, E, Ferrari, V, Borchiellini, D, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 2020;69:2513–22CrossRefGoogle ScholarPubMed